Johnson & Johnson Targets Multiple Myeloma Cure After Winning 6 of 12 New Drug Approvals
Updated
Updated · Johnson & Johnson · Jun 1
Johnson & Johnson Targets Multiple Myeloma Cure After Winning 6 of 12 New Drug Approvals
3 articles · Updated · Johnson & Johnson · Jun 1
Summary
Johnson & Johnson says it aims to make multiple myeloma curable in the near future, building on a portfolio that spans CAR-T cell therapies, bispecific antibodies and other targeted treatments.
About 6 of the 12 drugs approved for multiple myeloma over the past decade are Johnson & Johnson therapies, underscoring the company’s leading position in a cancer long described as incurable.
More than 700,000 patients worldwide have been treated with one of its approved myeloma therapies, while newer programs are moving into earlier treatment lines where patients often respond better.
Survival has improved sharply as treatment options expanded: patients once lived 2 to 3 years with therapy, while some now survive 10 years or more; the current five-year survival rate is 62%.
The company says broader combinations and stage-specific options are needed because the blood cancer typically relapses, grows more genetically complex and becomes harder to treat over time.